Literature DB >> 26622690

Survivin expression in lung cancer: Association with smoking, histological types and pathological stages.

Hiroshi Hirano1, Hajime Maeda2, Toshihiko Yamaguchi3, Soichiro Yokota3, Masahide Mori3, Saburo Sakoda3.   

Abstract

Survivin is expressed in the nucleus and/or cytoplasm of various malignant cells. Nuclear survivin is critical for the completion of mitosis, while cytoplasmic survivin functions as an inhibitor of apoptosis. The expression of survivin has been reported to be associated with the aggressiveness of certain types of cancer. The present study examined the association between cigarette smoking history and the expression of survivin and Ki-67 in lung adenocarcinomas of pathological (p) stages I, II and III. The expression of survivin and Ki-67 in adenocarcinomas was also compared with that of other p-stage I lung cancers, including squamous cell carcinoma (SqCC), large cell neuroendocrine carcinoma (LCNEC) and small cell carcinoma (SmCCs), of patients with a smoking history. In adenocarcinomas at p-stage I, labeling indices (LIs) of nuclear survivin and Ki-67 were significantly higher in tissue samples from smokers than those from non-smokers; however, the nuclear survivin and Ki-67 LIs in p-stage II and III adenocarcinomas from non-smokers and smokers were similar to those in p-stage I adenocarcinomas of smokers. The nuclear survivin and Ki-67 LIs in adenocarcinomas of smokers at p-stage I were lower than those in SqCCs, LCNECs and SmCCs of smokers at the same stage. Smokers with adenocarcinoma also exhibited a higher survival rate compared with that of smokers with SqCCs, LCNECs and SmCCs. The present results indicated that a history of smoking is associated with increased nuclear survivin and Ki-67 expression in lung adenocarcinomas of p-stage I, but not p-stages II or III. In addition it was revealed that, in smokers, the nuclear survivin and Ki-67 expression in p-stage I adenocarcinomas was lower than that of other p-stage I lung cancer types, and was associated with an enhanced survival rate. In conclusion, smoking is associated with the histogenesis of lung adenocarcinoma but not with the development of lung adenocarcinoma, based on the nuclear expression levels of Ki-67 and survivin.

Entities:  

Keywords:  Ki-67; histological type; lung cancer; smoking; survivin

Year:  2015        PMID: 26622690      PMCID: PMC4533747          DOI: 10.3892/ol.2015.3374

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  23 in total

1.  Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.

Authors:  Pablo E Vivas-Mejia; Cristian Rodriguez-Aguayo; Hee-Dong Han; Mian M K Shahzad; Fatma Valiyeva; Mineko Shibayama; Arturo Chavez-Reyes; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Clin Cancer Res       Date:  2011-04-21       Impact factor: 12.531

Review 2.  Survivin study: an update of "what is the next wave"?

Authors:  Fengzhi Li; Xiang Ling
Journal:  J Cell Physiol       Date:  2006-09       Impact factor: 6.384

3.  Survivin expression in gastric cancer: Association with histomorphological response to neoadjuvant therapy and prognosis.

Authors:  D Vallböhmer; U Drebber; P M Schneider; S Baldus; E Bollschweiler; J Brabender; U Warnecke-Eberz; S Mönig; A H Hölscher; R Metzger
Journal:  J Surg Oncol       Date:  2009-06-01       Impact factor: 3.454

4.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

5.  Differential localization and high expression of SURVIVIN splice variants in human embryonic stem cells but not in differentiated cells implicate a role for SURVIVIN in pluripotency.

Authors:  Amber N Mull; Amanda Klar; Christopher S Navara
Journal:  Stem Cell Res       Date:  2014-01-14       Impact factor: 2.020

6.  Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin.

Authors:  Piyali Dasgupta; Rebecca Kinkade; Bharat Joshi; Christina Decook; Eric Haura; Srikumar Chellappan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-06       Impact factor: 11.205

7.  Histological evaluation of the effect of smoking on peripheral small adenocarcinomas of the lung.

Authors:  Akiko Miyagi Maeshima; Naobumi Tochigi; Koji Tsuta; Hisao Asamura; Yoshihiro Matsuno
Journal:  J Thorac Oncol       Date:  2008-07       Impact factor: 15.609

8.  Nuclear survivin expression is associated with a poor prognosis in Caucasian non-small cell lung cancer patients.

Authors:  Yu-Lan Xie; Li An; Hao Jiang; Jing Wang
Journal:  Clin Chim Acta       Date:  2012-08-18       Impact factor: 3.786

9.  Nuclear survivin has reduced stability and is not cytoprotective.

Authors:  Claire M Connell; Rita Colnaghi; Sally P Wheatley
Journal:  J Biol Chem       Date:  2007-12-05       Impact factor: 5.157

10.  Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma.

Authors:  Soichiro Morinaga; Yoshiyasu Nakamura; Naoki Ishiwa; Takaki Yoshikawa; Yoshikazu Noguchi; Yuji Yamamoto; Yasushi Rino; Toshio Imada; Yoshinori Takanashi; Makoto Akaike; Yukio Sugimasa; Shoji Takemiya
Journal:  Oncol Rep       Date:  2004-12       Impact factor: 3.906

View more
  13 in total

1.  Factors that may influence polymorphous low-grade adenocarcinoma growth.

Authors:  Andresa Borges Soares; Elizabeth Ferreira Martinez; Patricia Fernandes Avila Ribeiro; Icleia Siqueira Barreto; Maria Cássia Aguiar; Cristiane Furuse; Marcelo Sperandio; Victor Angelo Montalli; Ney Soares de Araújo; Vera Cavalcanti de Araújo
Journal:  Virchows Arch       Date:  2017-02-10       Impact factor: 4.064

Review 2.  Epigenetic mechanism of survivin dysregulation in human cancer.

Authors:  Hui Lyu; Jingcao Huang; Zhimin He; Bolin Liu
Journal:  Sci China Life Sci       Date:  2018-01-04       Impact factor: 6.038

Review 3.  Insights into Novel Prognostic and Possible Predictive Biomarkers of Lung Neuroendocrine Tumors.

Authors:  Dimitrios Moris; Ioannis Ntanasis-Stathopoulos; Diamantis I Tsilimigras; Mohamad A Adam; Chi-Fu Jeffrey Yang; David Harpole; Stamatios Theocharis
Journal:  Cancer Genomics Proteomics       Date:  2018 Mar-Apr       Impact factor: 4.069

4.  Berberine-loaded liquid crystalline nanoparticles inhibit non-small cell lung cancer proliferation and migration in vitro.

Authors:  Keshav R Paudel; Meenu Mehta; Geena Hew Suet Yin; Lee Li Yen; Vamshikrishna Malyla; Vyoma K Patel; Jithendra Panneerselvam; Thiagarajan Madheswaran; Ronan MacLoughlin; Niraj Kumar Jha; Piyush Kumar Gupta; Sachin Kumar Singh; Gaurav Gupta; Pradeep Kumar; Brian G Oliver; Philip M Hansbro; Dinesh Kumar Chellappan; Kamal Dua
Journal:  Environ Sci Pollut Res Int       Date:  2022-02-16       Impact factor: 5.190

Review 5.  Cost-effectiveness of lung cancer screening and treatment methods: a systematic review of systematic reviews.

Authors:  Farbod Ebadifard Azar; Saber Azami-Aghdash; Fatemeh Pournaghi-Azar; Alireza Mazdaki; Aziz Rezapour; Parvin Ebrahimi; Negar Yousefzadeh
Journal:  BMC Health Serv Res       Date:  2017-06-19       Impact factor: 2.655

6.  Survivin protein expression is involved in the progression of non-small cell lung cancer in Asians: a meta-analysis.

Authors:  Liang Duan; Xuefei Hu; Yuxing Jin; Ruijun Liu; Qingjun You
Journal:  BMC Cancer       Date:  2016-04-18       Impact factor: 4.430

7.  CT45A1 siRNA silencing suppresses the proliferation, metastasis and invasion of lung cancer cells by downregulating the ERK/CREB signaling pathway.

Authors:  Feng Tang; Shengjun Tang; Xiaolong Guo; Chao Yang; Ke Jia
Journal:  Mol Med Rep       Date:  2017-09-12       Impact factor: 2.952

8.  Identification of a RNA-Seq based prognostic signature with five lncRNAs for lung squamous cell carcinoma.

Authors:  Rui-Xue Tang; Wen-Jie Chen; Rong-Quan He; Jiang-Hui Zeng; Liang Liang; Shi-Kang Li; Jie Ma; Dian-Zhong Luo; Gang Chen
Journal:  Oncotarget       Date:  2017-04-13

9.  Joint Transcriptomic Analysis of Lung Cancer and Other Lung Diseases.

Authors:  Beatriz Andrea Otálora-Otálora; Mauro Florez; Liliana López-Kleine; Alejandra Canas Arboleda; Diana Marcela Grajales Urrego; Adriana Rojas
Journal:  Front Genet       Date:  2019-12-06       Impact factor: 4.599

10.  Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Authors:  Rita Puskas; Andras Bikov; Peter Horvath; Zsofia Lazar; Laszlo Kunos; Reka Nagy; Gabriella Pinter; Gabriella Galffy
Journal:  Pathol Oncol Res       Date:  2021-04-30       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.